- Home
- TTRX vs MCGA Comparison
TTRX vs MCGA Comparison
Compare TTRX & MCGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TTRX | MCGA |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.8M | 243.8M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TTRX | MCGA |
|---|---|---|
| Price | $11.11 | $10.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 145.0K | 26.9K |
| Earning Date | 11-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $900.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $10.09 |
| 52 Week High | $16.45 | $10.69 |
Technical Indicators
Market Signals| Indicator | TTRX | MCGA |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 63.64 |
| Support Level | $9.02 | $10.16 |
| Resistance Level | $14.39 | N/A |
| Average True Range (ATR) | 1.25 | 0.01 |
| MACD | -0.41 | -0.00 |
| Stochastic Oscillator | 1.09 | 75.00 |
Price Performance
Historical ComparisonAbout TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
About MCGA Yorkville Acquisition Corp. Class A Ordinary Share
Yorkville Acquisition Corp is a blank check company.